Clinical Trials

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06124157 2026-05-27

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Lymphoid

Burkitt Lymphoma

NCT06820463 2026-05-27

AndroMETa-CRC

390 enrolled

Colorectal Neoplasms

NCT05712356 2026-05-26

BOLSTER

Phase 2 Terminated

66 enrolled 12 charts

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT06317662 2026-05-22

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT07603375 2026-05-22

TNT Esophagus

60 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT02890355 2026-05-20

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

123 enrolled 15 charts

Pancreatic Neoplasms

NCT06835387 2026-05-18

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

36 enrolled

Small Bowel Adenocarcinoma

NCT06948448 2026-05-18

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

144 enrolled

Colorectal Neoplasms

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT07432295 2026-05-14

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

66 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05836584 2026-05-13

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

240 enrolled

Clinical Stage I Gastric Cancer AJCC v8

NCT06792695 2026-05-11

CANTOR

120 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07554521 2026-05-11

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT04864067 2026-05-08

NOAHS-ARC

39 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT06094140 2026-05-06

NEO-IMPACT

20 enrolled

Pancreatic Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

176 enrolled

Pancreatic Neoplasms

NCT06941857 2026-05-05

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Carcinoma, Pancreatic Neoplasms

NCT02981628 2026-05-04

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Withdrawn

Borderline Resectable Pancreatic Adenocarcinoma

NCT07562711 2026-05-01

CLEAR-02

340 enrolled

Colorectal Neoplasms

NCT05004350 2026-04-30

NAUTICALCRC

107 enrolled 69 charts

Colorectal Neoplasms

NCT07559760 2026-04-30

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT05329766 2026-04-29

EDGE-Gastric

332 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06846346 2026-04-28

GRACIE

88 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT07381309 2026-04-28

VVSHIP

114 enrolled

Phase 2 Enrolling by invitation

CRC

NCT07441369 2026-04-27

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

16 enrolled

Liver Metastases From Colorectal Cancer (mCRC)

NCT07542002 2026-04-21

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

37 enrolled

Pancreatic Neoplasms

NCT02143219 2026-04-15

PAMELA70

72 enrolled 7 charts

Pancreatic Metastatic Cancer

NCT00792948 2026-04-13

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

97 enrolled 7 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03406299 2026-04-09

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

92 enrolled

Biliary Tract Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

3 enrolled

Stomach Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT03764553 2026-04-07

LyRICX

320 enrolled

Esophageal Neoplasms

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Neoplasms, Stomach Neoplasms

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

Colorectal Neoplasms

NCT06538623 2026-03-24

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

40 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

65 enrolled

Lymphoid

Lymphoma

NCT02359968 2026-03-18

PROTECT

106 enrolled

Esophageal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

60 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07474727 2026-03-16

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

180 enrolled

Colorectal Neoplasms

NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

171 enrolled

Burkitt Lymphoma, Leukemia

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

46 enrolled 15 charts

Pancreatic Neoplasms

NCT07070466 2026-03-06

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

40 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled